+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phenylethylamine and monoamine metabolites in CSF of schizophrenics: effects of neuroleptic treatment



Phenylethylamine and monoamine metabolites in CSF of schizophrenics: effects of neuroleptic treatment



Journal of Neural Transmission 57(1-2): 103-110



Phenylethylamine (PEA) and the monoamine metabolites 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) have been measured in the cerebrospinal fluid (CSF) of nine paranoid schizophrenics before and after three weeks of neuroleptic treatment. Patients were classified according to the Research Diagnostic Criteria and rated by means of the Brief Psychiatric Rating Scale. A significant increase was seen in HVA CSF concentrations during neuroleptic treatment (p less than 0.01). No influence was found on levels of PEA, 5-HIAA, and MHPG. Concentrations of both MHPG and 5-HIAA correlated positively with those of HVA. These results in combination with previous findings do not support the contention that PEA and NA metabolisms are grossly disturbed in paranoid schizophrenics whereas involvement of other neurotransmitters i.e. dopamine, seems more probable.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 043935131

Download citation: RISBibTeXText

PMID: 6194254

DOI: 10.1007/bf01250052


Related references

First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Biological Psychiatry 41(8): 857-864, 1997

Discriminative stimulus properties of beta-phenylethylamine, deuterated β-phenylethylamine, phenylethanolamine and some metabolites of phenylethylamine in rodents. Pharmacology Biochemistry and Behavior 24(6): 1547-1553, 1986

Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Archives of General Psychiatry 50(8): 606-614, 1993

Monoamines and monoamine metabolites in brains from demented schizophrenics. Acta Psychiatrica Scandinavica 60(1): 17-28, 1979

Discriminative stimulus properties of beta-phenylethylamine, deuterated beta-phenylethylamine, phenylethanolamine and some metabolites of phenylethylamine in rodents. Pharmacology, Biochemistry, and Behavior 24(6): 1547-1553, 1986

Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication. Zhonghua Shen Jing Jing Shen Ke Za Zhi 17(5): 273-277, 1984

Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. Journal Of Psychiatric Research. 29(3): 233-244, 1995

Serum concentrations of thioridazine, its major metabolites and serum neuroleptic-like activities in schizophrenics with and without tardive dyskinesia. Acta Psychiatrica Scandinavica 66(4): 294-305, 1982

Monoamine oxidase inhibitors potentiate phenylethylamine effects in rhesus monkeys. Biological Psychiatry 15(3): 429-436, 1980

MAO-B inhibitor treatment in Alzheimers disease Cognitive effects, behavioural changes and effects on CSF monoamine metabolites. Nicolini, M , Zatta, P F , Corain, B Advances in the Biosciences; Alzheimer's disease and related disorders : 457-460, 1993

The effects of lithium on phenylethylamine behavior in rats are counteracted by monoamine oxidase A and B inhibitors. Archives Internationales de Pharmacodynamie et de Therapie 233(2): 221-226, 1978

Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs. Progress in Biochemical Pharmacology 16: 133-140, 1980

In vivo relationship between monoamine oxidase type B and alcohol dehydrogenase: effects of ethanol and phenylethylamine. Life Sciences 43(4): 345-356, 1988

Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section 5(3): 193-202, 1993

Effects of phenylethylamine on cerebral cortical blood flow of mice lacking the monoamine oxidase B gene. Society for Neuroscience Abstracts 23(1-2): 1575, 1997